

GP Pharm

Quality and Technology to serve the patient

Biopharmaceutical Spanish Company

GP Pharm is a Pharmaceutical company of the Lipotec Group located in Barcelona (Catalonia, Spain). The company is focused on research, development, manufacturing and marketing of products for injection within Urology and Oncology fields, based in proprietary Drug Delivery Systems. These technological platforms include microspheres and liposomes.



Development capabilities

R&D Laboratories

Owned laboratories within its facilities located in Gavà (Barcelona). They are equipped with the last technologies available necessary to perform galenic and analytical developments and pilot tests.

Preclinical and clinical developments

4 studies published.

GP Pharm is leading different preclinical and clinical studies managed from its facilities located in Gavà (Barcelona).

Products under different preclinical studies: 8 products.

Products under different clinical studies: 3 products.



Comercial strategy

Products

Octreotide GP Pharm, Zuantrip 0,4mg[®] (Tamsulosin), Wibical 50mg[®] (Bicalutamide), Irinotecan, Paclitaxel, Oxaliplatin, Gemcitabine, Lutrate[®] (Leuprorelin depot).

Selling Force

GP Pharm has a net selling force operating in Spain for all of its oncological products. During 2009, it also has established subsidiaries in Portugal, Italy and Greece.

Licensing out

GP Pharm has given licenses to international pharmaceutical companies such as Sigma Tau, Nobel, CSC, Morgan, Campus Pharma, Habib Scientific, etc., in order to sell and distribute our products abroad.


Proprietary Technological Platforms

Microspheres

Platform based on the use of PLGA microspheres containing triethyl citrate to modulate a sustained drug release.

- Enhanced control during release phase
- Enhanced sustained release during the whole treatment
- Enhanced pharmacologic effect
- Decrease of the requested dose per administration unit.

Products: Leuprorelin 1 month, Leuprorelin 3 months, Triptorelin 1 month, Triptorelin 3 months, Gosorelin 3 months, Octreotide LAR, Octreotide MAR.



Liposomes

Platform based on liposomes for injection which includes the drug substance and lipochroman (a own proprietary antioxidant product) in the wall of the liposome.

- Suitable platform to encapsulate cytotoxic compounds to reduce its toxicity or increase its bioavailability.
- Reduces drug substance degradation process.

Products: Liposomal doxorubicin, target liposome's.



Manufacturing capabilities

GP Pharm owns a state of the art GMP facility of 3,000 sqm, sited in Sant Quintí de Mediona (60 Km from Barcelona), and included in a land size of 30,000sqm. This site is authorized to manufacture sterile forms of Cytotoxic products, High Potency products or different Drug Delivery forms.

Industrial scaling-up and commercial scale production

Production can be either in solution or freeze dried in different form: vials, ampoules and prefilled syringes. These facilities have capacity to scale-up from pilot batches to industrial scale batches for both platforms: microspheres and liposomes.



GP Pharm, S.A.

C/ Isaac Peral, 17 - Pol. Ind. Camí Ral
08850 Gavà - Barcelona (Spain)
Tel. +34 936 388 000 - Fax +34 936 389 535
www.gp-pharm.com